Stimatix GI

Results

Trendlines to report a loss for 1HFY2022 with US$7.9 mil portfolio company write-off

Trendlines is expected to report its results on Aug 10.

Broker's Calls

This start-up discoverer remains undervalued

SINGAPORE (July 3): Only 1% of the hundreds of leads that is being reviewed yearly by The Trendlines Group is selected to be its portfolio company.

Broker's Calls

Trendlines remains undervalued and 'overweight': NRA

SINGAPORE (June 28): NRA Capital is reiterating its “overweight” recommendation on Trendlines Group with a fair value estimate of 22.5 cents.

Trendlines reveals MVP Stimatix valued at US$43 mil

SINGAPORE (Apr 9): The Trendlines Group has revealed that colostomy-device company Stimatix GI is its “Most Valuable Portfolio" company.
×